-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

Benzinga·07/16/2026 09:49:49
语音播报
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.